MS research suggests the disease may be divided into two biological subtypes that differ in how early and aggressively nerve ...
The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback